Rheumatology · Clinical trials
Sjögren's Syndrome Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About sjögren's syndrome — and why its trials are hard
Sjögren's syndrome is a chronic autoimmune exocrinopathy characterized by lymphocytic infiltration of salivary and lacrimal glands, producing the hallmark sicca symptoms of dry eyes and dry mouth, alongside fatigue, arthralgia, and systemic manifestations. It may occur alone (primary) or with another connective-tissue disease (secondary), is strongly female-predominant, and carries an elevated risk of B-cell non-Hodgkin lymphoma. Serology typically shows anti-Ro/SSA and anti-La/SSB antibodies. Critically, there is no FDA-approved disease-modifying therapy: management is symptomatic, using artificial tears, secretagogues such as pilocarpine and cevimeline, topical cyclosporine for ocular disease, and off-label hydroxychloroquine or immunosuppressants for systemic features. Multiple biologic programs have failed to meet primary endpoints, including rituximab, abatacept, and tocilizumab, reflecting outcome-measure challenges, symptom-biology mismatch, and heterogeneous disease. The absence of an approved systemic therapy makes Sjögren's one of the largest unmet needs in rheumatology. Encouraging phase 2/3 signals with agents targeting the BAFF pathway and B cells (for example ianalumab and CD40-pathway blockers) have renewed hope, but as of 2026 none had achieved regulatory approval.
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in sjögren's syndrome development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Rituximab (anti-CD20) — TRACTISS and TEARS (phase 3/2) | Failed to significantly improve co-primary endpoints of fatigue and oral dryness (TRACTISS) | Symptom-driven endpoints poorly tracked B-cell depletion; high placebo response and disease heterogeneity |
| Abatacept (CTLA4-Ig) — ASAP-III (phase 3) | Did not meet primary endpoint of change in ESSDAI systemic activity | Insufficient separation from placebo on composite activity index |
| Tocilizumab (anti-IL-6R) — ETAP (phase 3) | Failed to improve disease activity (ESSDAI response) versus placebo | IL-6 blockade did not translate into meaningful systemic or symptomatic benefit |
Choosing the right endpoint
Primary endpoints that matter in sjögren's syndrome trials
- ESSDAI — EULAR Sjögren's Syndrome Disease Activity Index; physician-scored systemic activity, common primary endpoint
- ESSPRI — Patient-reported index of dryness, fatigue, and pain
- Unstimulated/stimulated salivary flow — Objective glandular function measure
- Schirmer test / ocular staining — Objective measures of tear production and ocular surface damage
How iNGENū runs sjögren's syndrome trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Sjögren's Syndrome clinical trials — FAQs
Is there an approved disease-modifying drug for Sjögren's?
Why have biologics failed in Sjögren's?
Is there hope for new therapies?
Ready to discuss your sjögren's syndrome trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal